Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Updates the ClinicalTrials.gov page’s displayed software/UI revision number from v3.5.2 to v3.5.3. This reflects a platform release rather than a change to the study record itself.
    Difference
    0.0%
    Check dated 2026-04-24T06:33:33.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and deleted Revision: v3.5.0 from the history.
    Difference
    0.0%
    Check dated 2026-04-17T02:46:02.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Difference
    0.0%
    Check dated 2026-04-02T15:34:23.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added to the Record History, replacing the older v3.4.3 entry.
    Difference
    0.0%
    Check dated 2026-03-19T05:59:36.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. No visible changes to trial information or page behavior.
    Difference
    0.0%
    Check dated 2026-03-12T00:47:11.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the history. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.
    Difference
    0.3%
    Check dated 2026-02-11T12:47:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.